| 59.553 -0.397 (-0.66%) | 05-13 15:44 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 78.7 | 1-year : | 84.83 |
| Resists | First : | 67.38 | Second : | 72.62 |
| Pivot price | 61.8  |
|||
| Supports | First : | 58.88 | Second : | 48.99 |
| MAs | MA(5) : | 59.96 |
MA(20) : | 63.51 |
| MA(100) : | 75.49 |
MA(250) : | 73.62 |
|
| MACD | MACD : | -3 |
Signal : | -2.9 |
| %K %D | K(14,3) : | 7.6 |
D(3) : | 5.7 |
| RSI | RSI(14): 26.4 |
|||
| 52-week | High : | 89.83 | Low : | 58.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ COO ] has closed above bottom band by 21.1%. Bollinger Bands are 0.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 60.5 - 60.9 | 60.9 - 61.26 |
| Low: | 57.9 - 58.41 | 58.41 - 58.87 |
| Close: | 59.16 - 59.97 | 59.97 - 60.7 |
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Wed, 13 May 2026
Cooper Companies earnings preview: What to expect - MSN
Tue, 12 May 2026
Number of shareholders of The Cooper Companies, Inc. – NASDAQ:COO - TradingView
Wed, 06 May 2026
COO Stock Price Prediction 2025-2026 | The Cooper Companies, Inc Forecast - 24/7 Wall St.
Thu, 30 Apr 2026
CooperCompanies sets June 4 earnings release, 5 p.m. ET call - Stock Titan
Wed, 29 Apr 2026
Cooper Companies stock hits 52-week low at 61.76 USD - Investing.com
Fri, 24 Apr 2026
Cooper Cos Inc/The (NASDAQ:COO): A Decent Value Opportunity in the Healthcare Sector - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 195 (M) |
| Shares Float | 194 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 105.8 (%) |
| Shares Short | 5,520 (K) |
| Shares Short P.Month | 5,590 (K) |
| EPS | 2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 42.86 |
| Profit Margin | 9.6 % |
| Operating Margin | 20.7 % |
| Return on Assets (ttm) | 3.6 % |
| Return on Equity (ttm) | 4.8 % |
| Qtrly Rev. Growth | 6.1 % |
| Gross Profit (p.s.) | 13.94 |
| Sales Per Share | 21.27 |
| EBITDA (p.s.) | 5.63 |
| Qtrly Earnings Growth | 26.8 % |
| Operating Cash Flow | 866 (M) |
| Levered Free Cash Flow | 367 (M) |
| PE Ratio | 29.73 |
| PEG Ratio | 1.6 |
| Price to Book value | 1.39 |
| Price to Sales | 2.81 |
| Price to Cash Flow | 13.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|